Its roles Owner Operator Developer
Roche (Roche Holding AG) is a global healthcare company headquartered in Basel, Switzerland, focused on the research, development, and manufacturing of pharmaceuticals and diagnostics. The group operates through two core divisions—Pharmaceuticals and Diagnostics—and includes subsidiaries such as Genentech in the United States and Chugai in Japan.
For the chemical and life sciences value chain, Roche develops small‑molecule medicines and active pharmaceutical ingredients (APIs) alongside a broad portfolio of biologics, including monoclonal and bispecific antibodies. Its capabilities span process chemistry, analytical development, scale‑up, and GMP manufacturing, as well as large‑scale cell culture, purification, and fill‑finish operations. The Diagnostics division provides in vitro diagnostic systems, reagents, and molecular testing technologies. Roche’s therapeutic focus areas include oncology, immunology, infectious diseases, neuroscience, and ophthalmology. The company maintains a global R&D and manufacturing network and emphasizes regulatory compliance, quality, and reliable supply across its operations.
Also known as Roche Group, Roche Holding AG, Roche Diagnostics GmbH, Roche Diagnostics, F. Hoffmann-La Roche and 1 more.
chemXplore tracks 2 projects involving Roche, of which one is active.
Besides this one, the record holds 1 completed project.
Closest to start-up first.
The 1 that is completed, on hold or cancelled are in the record. See all 2 in chemXplore →
Automated IHC assay to distinguish malignant mesothelioma from mimics, registered with FDA and IVDR, and designed to preserve tissue for downstream molecular testing.
Compact benchtop immunoanalyser (~0.9 m²) with 36 reagent positions, planned >100-assay menu, Elecsys reagent compatibility, and reaction times ≤18 minutes for most tests.
Chugai links to Roche’s ASN Kidney Week 2026 media release presenting interim IMAgINATION data that show sefaxersen significantly reduced proteinuria.
Phase III Krascendo 1: divarasib reduced risk of progression/death by 42% and risk of death by 44%; median OS ~17.7 vs 12.0 months; ORR 58% vs 32%; manageable safety.
Phase III data show once‑monthly ASO sefaxersen reduced proteinuria versus placebo at 37 weeks in adults with IgA nephropathy, with consistent subgroup effects and no new safety signals.
Group sales +6% (CER) in first nine months; Q3 +7% (CER)/+8% CHF. Pharmaceuticals drove growth, diagnostics up despite China pricing reforms. 2026 outlook confirmed.
Phase III fenebrutinib data show reduced chronic active MS lesions and a 55% ARR cut; Ocrevus shows durable pediatric and older-adult control; Enspryng supports MOGAD attack reduction.
Late‑stage results show divarasib superiority in KRAS G12C NSCLC, giredestrant preserves quality of life while improving efficacy, and Tam‑Peli shows robust activity in nasopharyngeal carcinoma.
active all projects
